DSP Nabs U.S. and Canadian Marketing Option to SanBio’s Phase I Cell Therapy

Japanese pharma, Dainippon Sumitomo Pharma, has agreed to co-develop California-based SanBio’s stem cell therapy, SB623, for the treatment of stroke. SB623 is a modified bone marrow derived stem cell therapy that has the potential to translate as an ALS treatment.

Click here to read more.

Share this: